Boehringer Ingelheim has moved one of its top pipeline prospects – oral phosphodiesterase 4B (PDE4B) inhibitor BI 1015550 – into late-stage clinical testing for idiopathic pulmonary fibrosis ...

Veterinary Glucometers MarketThe veterinary glucometers market is set for robust growth, with a projected value of USD 351.3 ...

The University of Tennessee College of Veterinary Medicine has deployed its large animal ambulatory truck to Carter County, ...

The University of Tennessee College of Veterinary Medicine (UTCVM) is deploying its mobile veterinary clinic to Carter County ...

Denmark's Zealand Pharma and German partner Boehringer Ingelheim have won the U.S. Food and Drug Administration's Breakthrough Therapy for the review of their experimental weight-loss drug for the ...

By Andrew Pollack Hikma Pharmaceuticals agreed to pay about $2.65 billion in cash and shares for Boehringer Ingelheim’s generic drugs business in the United States. Boehringer Ingelheim said ...

The global nasal sprays market is on an exceptional growth trajectory, projected to reach an impressive USD 32.6 billion by 2033, according to a recent study by Future Market Insights. A robust ...

Boehringer Ingelheim has started a registration trial of its experimental therapy brigimadlin as a treatment for dedifferentiated liposarcoma (DDLPS), a rare cancer with limited treatment options.

The Global Veterinary Antiseptic Market was valued at approximately USD 3.47 billion in 2023 and is anticipated to grow to at a compound annual growth rate (CAGR) of 7.2% during the forecast period ...

Hosted by Boehringer Ingelheim, the ‘CRM Summit’, an expert engagement forum, and the ‘IMETA CRM Discussions for EXperts (MEDEX CRM)’, a scientific expert meeting, brought together healthcare ...

She's currently the Chief Medical Officer and Head of Medicine at Boehringer Ingelheim. Well, Dr. Hinsch Gylvin. Thanks for joining me today. That really has changed. So first and foremost ...